Alex Dale, Author at Labiotech.eu

About

A former journalist intern at Labiotech, Alex now works as a copywriter in healthcare advertising. When he’s not writing, he enjoys playing sports and long-distance cycling.

Articles by Alex Dale

News and Trends 25 Jan 2018

Yet More Good News for GW Pharma’s Cannabinoid Drug Against Epilepsy

New data in The Lancet provides further support for GW Pharma’s drug, Epidiolex, for the treatment of a rare form of epilepsy. GW Pharmaceuticals has achieved encouraging Phase III results for Epidiolex, which have been published in leading scientific journal, The Lancet. The company’s lead candidate is being developed for the treatment of epilepsy – a […]

January 25, 2018 - 3 minutesmins - By Alex Dale

News and Trends 25 Jan 2018

British Biotech Treats First Phase III Patient in its Critical Limb Ischemia Trial

Rexgenero has treated the first patient in a Phase III trial investigating REX-001, the biotech’s cell therapy for critical limb ischemia. Rexgenero is a biotech working on regenerative medicine techniques to treat critical limb ischemia (CLI). The condition is characterized by blocked arteries in the lower limbs that can force doctors to amputate. The company has […]

January 25, 2018 - 3 minutesmins - By Alex Dale

News and Trends 25 Jan 2018

Researchers Take Aim at Pancreatic Cancer with a Modified Flu Virus

In an early study at Queen Mary University in London, a modified flu virus has been able to block the growth of pancreatic cancer. For the first time, researchers at Queen Mary University, London, have shown that pancreatic cancer can be targeted using a modified flu virus. During a study, published in Molecular Cancer Therapeutics, […]

January 25, 2018 - 3 minutesmins - By Alex Dale

News and Trends 24 Jan 2018

New Retinitis Pigmentosa Treatments? This Blood-Retina Chip Could Help!

A new ‘organ-on-a-chip’ device for the blood-retina barrier could speed up the development of treatments for eye diseases like retinitis pigmentosa. Researchers from Microelectronics Institute of Barcelona, Vall d’Hebron Research Institute, and Universitat Autònoma de Barcelona have developed a microfluidic chip that mimics the human blood-retinal barrier in the eye. The study, published in Lab on a […]

January 24, 2018 - 3 minutesmins - By Alex Dale

News and Trends 24 Jan 2018

Biotech and Pharma Boost R&D and Slow Sales to Beat Antibiotic Resistance

To fight antibiotic resistance, the independent report found that companies are developing new drugs, discouraging their overselling, limiting their run-off into wastewater, and tracking the spread of superbugs. Antibiotics are becoming ineffective at an alarming rate due to our misuse in healthcare, animals, and crops. Antibiotic resistance is responsible for 700,000 deaths each year, which is expected to continue […]

January 24, 2018 - 3 minutesmins - By Alex Dale

News and Trends 24 Jan 2018

No Entry! This Protein Could Stop Breast Cancer from Escaping to the Rest of the Body

Spanish scientists have found genes that maintain breast cancer cells in a dormant state, which could be manipulated to control the spread of the disease. The time taken for breast cancer to spread varies among patients and not much is known about the mechanisms that control it. Researchers at the Institute for Research in Biomedicine […]

January 24, 2018 - 3 minutesmins - By Alex Dale

News and Trends 23 Jan 2018

NASH Leader goes Pediatric with Clinical Trial Launch in US

The FDA has cleared Genfit to kick off clinical trials to see if its NASH drug, elafibranor, can also help children. Genfit develops diagnostic and therapeutic tools for metabolic and inflammatory diseases, particularly those affecting the liver. Its lead candidate, elafibranor, targets Non-Alcoholic Stato-Hepatitis (NASH), and the company’s plan to begin testing it in children has been supported […]

January 23, 2018 - 2 minutesmins - By Alex Dale

News and Trends 23 Jan 2018

Swedish Biotech Can Now Fast-Track its Metabolic Disorder Drug

Sobi will enter the clinic after the Investigational New Drug application for its rare metabolic disorder candidate was accepted by the FDA. The Swedish Orphan Biovitrum (Sobi) will begin clinical trials for SOBI003, its candidate for the rare metabolic disorder, Sanfilippo syndrome type A. This was made possible as the FDA’s accepted the company’s Investigational New Drug […]

January 23, 2018 - 2 minutesmins - By Alex Dale

In Depth 23 Jan 2018

Walking with the Dinosaurs of European Biotech: Which of Them is Roaring the Loudest?

Although biotech may seem like an industry that has only just gotten started, it was already up and running before the turn of the century. We took a look back at the pre-2000 companies to see how they’re faring. According to our biotech map, there were 219 biotechs in Europe in 1999. Today, our map […]

January 23, 2018 - 10 minutesmins - By Alex Dale

News and Trends 22 Jan 2018

European Court Supports the Softening of CRISPR Gene Editing Rules

The tough regulations that apply to genetically modified organisms may no longer affect plants and animals created using CRISPR gene editing technology. The European Court of Justice has ruled that crops and drugs developed using precise gene-editing techniques like CRISPR/Cas9 may not need to be regulated as strictly as genetically modified organisms (GMOs). So far, […]

January 22, 2018 - 3 minutesmins - By Alex Dale

News and Trends 22 Jan 2018

New Triple Combination Therapy Boosts Colorectal Cancer Survival

Pierre Fabre and Array BioPharma’s combination therapy for colorectal cancer has improved progression-free survival in a Phase III trial. French pharma Pierre Fabre and American biopharma Array BioPharma, has carried out an initial safety lead-in study for a Phase 3 trial evaluating a triple combination therapy for the treatment of metastatic colorectal cancer patients. The therapy was […]

January 22, 2018 - 3 minutesmins - By Alex Dale

News and Trends 22 Jan 2018

Novartis Takes Genmab’s Leukemia Drug Off the Market

Genmab’s leukemia drug will be available around the world through compassionate use programs, while it will continue to be marketed as normal in the US. Blockbuster drug owner Genmab developed Arzerra for the treatment of chronic lymphocytic leukemia (CLL) but the drug will be taken off the market outside the US due to its low uptake. Novartis markets the drug and […]

January 22, 2018 - 3 minutesmins - By Alex Dale

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Alex Dale

About

Articles by Alex Dale

Yet More Good News for GW Pharma’s Cannabinoid Drug Against Epilepsy

British Biotech Treats First Phase III Patient in its Critical Limb Ischemia Trial

Researchers Take Aim at Pancreatic Cancer with a Modified Flu Virus

New Retinitis Pigmentosa Treatments? This Blood-Retina Chip Could Help!

Biotech and Pharma Boost R&D and Slow Sales to Beat Antibiotic Resistance

No Entry! This Protein Could Stop Breast Cancer from Escaping to the Rest of the Body

NASH Leader goes Pediatric with Clinical Trial Launch in US

Swedish Biotech Can Now Fast-Track its Metabolic Disorder Drug

Walking with the Dinosaurs of European Biotech: Which of Them is Roaring the Loudest?

European Court Supports the Softening of CRISPR Gene Editing Rules

New Triple Combination Therapy Boosts Colorectal Cancer Survival

Novartis Takes Genmab’s Leukemia Drug Off the Market

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Alex Dale

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!